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Aims: As cardiac performance is closely related to its energy supply, our study investigated the effect of the
orotic acid cardioprotective agent on the pathways of energy supply, in both conditions of normal ﬂow and
ischemia.
Main methods: Male Wistar rats were fed during nine days with a balanced diet only or supplemented with
1% orotic acid.
Key ﬁndings: Dietary administration of orotic acid increased the cardiac utilization of fatty acids, activity of
the lipoprotein lipase, expression of the gene of peroxisome proliferator-activated receptor α and its target
enzymes. In addition, orotic acid increased the myocardial uptake and incorporation of glucose, glycogen
content and level of GLUT4, concentration of glycolytic metabolites and lactate production in both experi-
mental conditions, baseline and after regional ischemia.
Signiﬁcance: Thus, in orotic acid hearts there was a simultaneous stimulus of fatty acid oxidation and glyco-
lytic pathway, reﬂected in increased energetic content even in pre-ischemia. The analysis of the cardiac con-
tractility index showed a positive inotropic effect of orotic acid due, at least in part, to the increased
availability of energy. The result allows us to suggest that the metabolic changes induced by orotic acid result
in appreciable alterations on myocardial contractile function.© 2012 Elsevier Inc. Open access under the Elsevier OA license.Introduction
Functional cardiac performance is closely related to the energetic
metabolism of the heart and several experimental and clinical studies
have shown that therapeutic agents that optimize the cardiac energetic
yield constitute important approaches to the treatment of cardiac
dysfunction. In this context, orotic acid (OA), an intermediate in the bio-
synthetic pathway of pyrimidines, has beneﬁcial cardiovascular effects,
improving post-ischemic myocardial function (Ferdinandy et al., 1998;
Munsch et al., 1989; Rosenfeldt, 1998). OA is found in low concentra-
tions in nucleated cells and in many biological ﬂuids and the major
dietary intake of this component in humans is in bovine milk (80 mg/L)
(Morifuji and Aoyama, 2002).
It has been reported that post-infarcted hearts treated with OA
present greater availability of ATP and, therefore, better post-ischemicentos, Universidade Federal de
9 1409.
vier OA license.efﬁciency (Rosenfeldt, 1998). Other studies have shown that treatment
of rats with OA increased the glycogen content of normoxic and ische-
mic hearts, with signiﬁcant improvement in post-ischemic myocardial
function (Ferdinandy et al., 1998; Munsch et al., 1989) and have sug-
gested that synthesis of ATP and total adenine nucleotides can occur
by stimulation of glucose uptake, via uridine, and consequent glycolysis
for anaerobic production of energy (Donohoe et al., 1993). The chal-
lenge is, therefore, to optimize cardiac energetic yield, enabling the
tissue to minimize the post-ischemia and reperfusion intracellular
ionic overload and to ensure the vital cardiac functions. Given the fore-
going, we aimed at providing new insights into the mechanism of OA
on cardiac energetic optimization. To accomplish this, we have investi-
gated relevant parameters of metabolic pathways generating energy
in rat hearts following dietary supplementation with OA.
The energy supply of the heart is met by joint use of different sub-
strates. However, under normal aerobic conditions the fatty acids
(FA) and glucose constitute the major sources of energy, with FA con-
tributing about 60–90% of this energy supply (Armoni et al., 2005;
Depre et al., 1999; Sambandam and Lopaschuk, 2003; Schmidt et al.,
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tissue and lipoprotein lipase (LPL) is rate-limiting for the hydrolysis
of TG contained in these molecules (An et al., 2005; Niu et al., 2004;
Pulinilkunnil et al., 2003; Teusink et al., 2003).
The peroxisome proliferator-activated receptor α (PPARα) is the
key transcriptional regulator of genes involved in FA oxidation, being
directly connected to the control of the expression and activity of
enzymes of the mitochondrial and peroxisomal oxidation of FA, such
as carnitine palmitoyltransferase-1 (CPT-1) and acyl-CoA oxidase
(ACO), respectively (Nohammer et al., 2000; Totland et al., 2000).
The free fatty acids (FFA) are captured by cardiac cells and the transfer
of fatty acyl moieties into mitochondria is catalyzed by CPT-1
(Nohammer et al., 2000; Totland et al., 2000). Peroxisomal oxidation
also contributes to the energy generation and in this process the
ACO plays a key role (An et al., 2005; Hajri and Abumrad, 2002; Katz,
2006; Niu et al., 2004; Nohammer et al., 2000; Sambandam and
Lopaschuk, 2003; Totland et al., 2000). The transport of glucose into
the cardiomyocyte is regulated by speciﬁc transporters, the GLUTs
and the isoform predominant on the adult cardiomyocyte is GLUT4,
the insulin-sensitive transporter (Depre et al., 1999). It has been
widely accepted that adenosine monophosphate-activated protein
kinase (AMPK) activation has a great impact on substrate metabolism
in the heart via induction of GLUT4 translocation (Sambandam and
Lopaschuk, 2003).
In this work we investigated the effect of OA on important meta-
bolic steps involving the use of FA and glucose by myocardial tissue
and the outcomes for energy yield and contractile function in rats,
under normal ﬂow and ischemic conditions. We demonstrate that in
OA hearts there was a simultaneous stimulus of fatty acid oxidation
and glycolytic pathway. This metabolic rearrangement was reﬂected
in increased cardiac energetic content even in pre-ischemia, particu-
larly important for maintaining the residual pool of ATP during the
ischemic phase.
Materials and methods
Materials
Orotic acid was obtained from Aldrich (USA); bovine serum albu-
min (Bovuminar Reagent Pure Powder) was obtained from Intergen
(Purchase, NY); [9,10-3H] triolein and [14C] glucose were obtained
from Perkin Elmer Life and Analytical Sciences (Boston, USA); rabbit
anti-Glut4 polyclonal antibody was obtained from Chemicon Interna-
tional; rabbit anti-AMPK (phospho-Thr172) polyclonal antibody was
obtained from ABCAM; triolein, G-6-P dehydrogenase, phosphoglu-
cose isomerase, hexokinase, mouse anti-beta actin monoclonal anti-
body and anti-rabbit and anti-mouse IgG peroxidase conjugate were
obtained from Sigma (USA); ECL plus blotting detection reagent
was obtained from Amersham (GE Healthcare, Little Chalfont, UK);
Trizol® reagent and MMLV (Moloney murine leukemia virus) were
obtained from Invitrogen Life Technologies (San Diego, CA) and the
speciﬁc primers from Invitrogen Life Technologies (Brazil); and kit
SYBR Green PCR core reagents were obtained from Applied Biosystems.
All other chemicals were of analytical grade obtained commercially.
Animals and treatment
All animals were cared for in accordance with the principles pro-
mulgated by Ethical Guidelines and the experimental protocol was
approved by the “Ethics Committee in Animal Experimentation of the
Federal University of Minas Gerais” (protocol no. 027/05). Wistar male
rats (8–10 weeks old) were obtained from the Breeding Center of the
Federal University of Minas Gerais (UFMG); kept in individual cages in
an environmentally controlled room with a 14/10 h light/dark cycle
and had free access to tap water and food. The animals were divided
into 2 experimental groups — 1) fed with a balanced diet (C — controlgroup) consisting of 58% carbohydrate (29% starch and 29% sucrose),
7% corn oil, 18% casein, 4% salts, 1% vitamins and 12% humidity
(Kettelhut et al., 1980); and 2) fed with a balanced diet supplemented
with 1% OA (OA group) — which were fed during 9 days (Ferreira et
al., 2008), after 2 days of adaptation to these diets. The OA administra-
tion has been reported to be effective in reducing the extent of the
infarcted area in rats (Ferdinandy et al., 1998; Munsch et al., 1989;
Rosenfeldt, 1998). Food intake was carefully monitored by weighing
daily special feeding containers and the weight gain was obtained by
weighing the animals on the ﬁrst and ninth days of feeding. The animals
were killed between 13:00 h and 14:00 h and the hearts were collected
and used immediately or stored at−80 °C. The serum was isolated and
stored at−20 °C until further analysis.
Langendorff isolated heart perfusion
The rats were decapitated, the thoracic cavities were opened and
the hearts quickly excised and perfused to avoid clotting in the coronary
arteries. Immediately on excision, the beating hearts were immersed in
cold (4 °C) Krebs-Ringer (K-R) buffer (pH 7.4) containing 118.4 mM
NaCl, 4.7 mM KCl, 1.2 mM KH2PO4, 1.2 mM MgSO4·7H2O, 2.5 mM
CaCl2·2H2O, 11.7 mM glucose and 26.5 mM NaHCO3. They were then
cannulated via the aorta and perfused retrogradely through the coro-
nary arteries in Langendorff mode, using the K-R buffer plus 1% bovine
serum albumin. The perfusion ﬂuid was maintained at 37±1 °C, with
a pressure of 65 mmHg and gassed continuously (5% CO2; 95%O2).
A force transducer (model FT 03, Grass) was attached through a
heart clip to the apex of the ventricles to record the contractile force
(tension, g) on a computer, by a data-acquisition system (Codas,
Dataq Instruments Inc., Akron, OH, USA). A diastolic tension of 0.5 to
1.0 g was applied to the hearts. The heart rate (HR) and dT/dt were
derived from the changes in cardiac tension wave by the acquisition
system. The coronary ﬂow was measured by collecting the perfusate
over a period of 1 min at regular intervals. On the models submitted
to regional ischemia, the left anterior descending coronary artery was
ligated beneath the left auricular appendage, togetherwith the adjacent
veins (Lubbe et al., 1978). The ligature was released after 15 min and
the reperfusion was performed for an additional 15 min. To measure
the activity of the functional LPL, after an initial 20 min stabilization
period, 5 IU.mL−1 heparin was added to the perfusion solution and
the perfusates were then collected at regular intervals.
Lipoprotein lipase (LPL) activity
To estimate the total LPL activity, samples of intact cardiac tissue
(50 mg) were homogenized in buffer containing heparin and deter-
gents (Iverius and Ostlund-Lindqvist, 1986). The enzymatic activity
was measured using a [9,10-3H]triolein-containing substrate emulsi-
ﬁed with lecithin (Nilsson-Ehle and Schotz, 1976) and contained
24 h fasted rat serum as a source of apo CII. The serum was pre-
treated by heating to 55 °C to inactivate non-speciﬁc plasma lipases.
The radioactivity in liberated fatty acids was counted following ex-
traction in methanol–chloroform–heptane (Belfrage and Vaughan,
1969). Functional LPL (the active LPL released by heparin) was mea-
sured directly in cardiac perfusate after heparin injection in the perfu-
sion solution.
Quantitative real-time PCR
Total RNA from hearts was extracted using TRIzol reagent, treated
with DNAse and reverse transcribed with MML-V (Moloney murine
leukemia virus) (adapted from [22]). cDNAwas ampliﬁed using speciﬁc
primers of PPARα (forward: 5′-taccactatggagtccacgcatgt-3′; reverse: 5′-
ttgcagcttcgatcacacttgtcg), CPT-1 (forward: 5′-acgtgagtgactggtgggaa-
gaat-3′; reverse: 5′-tctccatggcgtagtagttgctgt-3′), ACO (forward: 5′-
atctctgtggttgctgtggagtca-3′, reverse: 5′-tctggatgcttccttctccaaggt-3′),
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ctgcttgctgatccacatctg-3′) and SYBR® Green PCR buffer in an ABI
Prism 7000 platform (Applied Biosystems). β-Actin was co-ampliﬁed
as an endogenous normalizing gene. The speciﬁc primer sequence
was designed from sequences available in GenBank (BLAST, NCBI).
The ampliﬁcation parameters were set at stage 1 — one cycle at 50 °C
for 2 min, stage 2 — one cycle at 95 °C for 10 min, stage 3 — 40 cycles
of 95 °C for 0.15 min and 60 °C for 1 min. To analyze the target gene
expression, we used the ΔΔCT semi-quantitative method (Livak and
Schmittgen, 2001). The expression levels were represented as the
ratio of signal intensity for each target mRNA relative to β-actin mRNA.Western blotting analysis
Samples of frozen cardiac ventricles (~300 mg) were homoge-
nized in lysis buffer containing protease and phosphatase inhibitors.
After centrifugation at 1500 g for 20 min at 4 °C, the protein content
of the supernatant was quantiﬁed using a Bradford protein assay
and, then, 50 μg was resolved on SDS-PAGE (10%). After transfer,
the membranes were blocked in 5% skim milk in Tris-buffered
saline containing 0.1% Tween 20. The glucose transporter GLUT4
was probed with a polyclonal rabbit anti-GLUT4 antibody (1:4000),
phospho-AMPK (Thr172) was probed with a polyclonal rabbit anti-
AMPK antibody (1:1000) and goat anti-rabbit IgG antibody conju-
gated with peroxidase (1:2000) was used as a secondary antibody.
The blots were visualized using an ECL® chemiluminescence detec-
tion kit.Biochemical analysis
Ventricular tissues were freeze-dried and the metabolites were
extractedwith perchloric acid for determination of ATP, glycolytic inter-
mediates (G-6-P, glucose-6-phosphate; F-6-P, fructose-6-phosphate)
and glycogen. The extractswere then assayed enzymatically using spec-
trophotometricmethods (Pôrto et al., 2011). The total glycogen content
was quantiﬁed by the anthrone assay (Pôrto et al., 2011). Serum triglyc-
erides, total cholesterol and glycerol were assayed by conventional
enzymatic methods using kits produced by Katal (Belo Horizonte,
MG). Free fatty acids were estimated using commercial kits from
Wako (Pure Chemical Industries, Japan). The lactate present in cardiac
perfusatewas quantiﬁed by using a glucose and lactate oxidase analyzer
(Glucose analyzer YSI 300 Plus).Table 1
General and serum parameters from C (control) and OA (orotic acid) animals.
C OA
General (n=5)
Food intake (g/day) 21±0.7 22±1.2
Final body weight (g) 242±8.6 241±5.7
Body weight gain (g/9 days) 61±6.8 58±5.9
Heart weight (g/100 g bw) 0.41±0.01 0.41±0.01
Serum (n=6)
Triglycerides (mmol/L) 1.56±0.12 0.30±0.03⁎⁎⁎⁎
Total cholesterol (mmol/L) 4.28±0.09 1.88±0.21⁎⁎⁎⁎
Free fatty acid (mmol/L) 0.74±0.05 1.61±0.09⁎⁎
Glycerol (mmol/L) 0.56±0.04 0.66±0.03
Data are means±SEM.
⁎⁎⁎⁎ pb0.0001 vs C.
⁎⁎ pb0.01 vs C.Measurements of uptake and incorporation of energy substrates
To investigate the utilization of energy substrates, we adapted the
method described by Golfman et al. (2005) and Niu et al. (2004).
During stabilization, the hearts were perfused in a non-recirculating
Langendorff mode, explained above. Then, the system was switched
to a recirculating mode using K-R buffer containing only 3H-triolein
(15 μCi/L) or 3H-triolein (15 μCi/L) and [U-14C] glucose (10 Ci/L),
and insulin. The substrate-emulsion (adapted from Faraj and
Cianﬂone, 2004) was added to the K-R solution at a ﬁnal concentra-
tion of 0.4 mM triolein and the glucose concentration was 5.5 mM.
Aliquots of 1 mL perfusate were collected at regular intervals for
30 min and the uptake of energetic substrates was determined indi-
rectly by measuring the disappearance of these components from
the perfusate during 30 min. Incorporation was investigated directly
in fragments of cardiac ventricles. The samples were subjected to
lipid extraction with chloroform:methanol (2:1, v/v) (Folch et al.,
1957), so that the uptake and incorporation of FA were measured in
the organic phase and the uptake and incorporation of glucose were
measured analyzing the aqueous phase for radioactivity.Statistical analysis
Data are expressed as mean±S.E. The statistical signiﬁcance
between the groups was assessed by unpaired Student's t test, two-
way ANOVA (with post hoc Bonferroni test) and one-way ANOVA
(with post hoc Newman Keuls test) according to viability. All data
and statistical analyses were performed using GraphPad Prism
version 4.0 for Windows, GraphPad Software, San Diego, California,
USA. Differences were considered statistically signiﬁcant at the
pb0.05 level.
Results
The dietary supplementation with OA for 9 days did not modify
body weight gain and cardiac tissue weight, compared to control
diet in rats. Also, the food intake was similar among the groups
(Table 1). In relation to serum parameters, the OA animals displayed
a decrease in triglycerides (81% of decrease) and total cholesterol
(52% of decrease) concentration. The FFA concentration was increased
by 44% in the OA group of rats, compared to the control group, whereas
no change was observed in glycerol concentration (Table 1).
As the lipoproteins constitute the main sources of FA used by
the heart muscle and the LPL is the enzyme that hydrolyzes the
core of triglyceride-rich lipoproteins into FFA and monoglycerides,
we measured the total and functional LPL activity. The OA hearts
presented a 58% increase in total LPL activity (Fig. 1A). The activity
of the heparin-released enzyme fraction also was increased during
the basal and ischemic perfusion (53% increase) (Fig. 1B). The analy-
sis of triolein-FA uptake and incorporation conﬁrmed the results
above (Fig. 1C, D). Dietary administration of OA increased the cardiac
uptake of FA in both, perfusion with 3H-triolein only and on perfusion
with 3H-triolein plus [U-14C] glucose simultaneously, compared to
control diet (Fig. 1C). After perfusion with 3H-triolein alone, cardiac
incorporation of FA by OA hearts was also major than that of C hearts
(Fig. 1D). Addition of glucose to perfusion buffer caused the expected
decrease in FA uptake by OA hearts (30% decrease) (Fig. 1C) and in FA
incorporation in both groups (92% and 95% decrease for C and OA
groups, respectively) (Fig. 1D). In order to analyze the utilization
of energy substrates, the perfusion system was switched to a recircu-
lating mode using K-R buffer containing only 3H-triolein and glucose
or 3H-triolein, [U-14C] glucose and insulin (40 μU/mL), at a ﬁnal con-
centration of 0.4 mM triolein and 5.5 mM glucose.
We investigated the lipid oxidative pathway by quantifying the
gene expression of an important transcriptional regulator, PPARα, and
of its target enzymes, CPT-1 and ACO. Real-time PCR quantiﬁcation
was performed to measure mRNA using speciﬁc primers for PPARα,
CPT-1 or ACO, and the β-actin housekeeping gene was used as internal
control after reverse transcription analyses. The results show that OA
Fig. 1. Lipoprotein lipase activity and 3H-triolein-FA utilization by hearts from control (C) and orotic acid (OA) treated rats. A: total LPL activity determined in myocardial tissue
samples; B: heparin-releasable LPL activity determined in cardiac perfusate, in basal conditions and during occlusion and reperfusion. Total uptake (C) and tissue incorporation
(D) of 3H-triolein-FA by hearts perfused with 3H-triolein only or with 3H-triolein, [U-14C] glucose and insulin simultaneously. Data are means±SEM for n=7 animals; *pb0.05 vs C;
****pb0.0001 vs C; ***pb0.001 vs C for triolein alone, ###pb0.001 vs C for triolein+glucose, ●●pb0.01 vs corresponding value for triolein alone, and ●●●, +++pb0.001 vs corresponding
value for triolein alone.
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increase) (Fig. 2A) and similarly for cardiac CPT-1 (1836% increase)
(Fig. 2B) and ACO (90% increase) (Fig. 2C) mRNA, in relation to control.
The OA treated hearts showed 290% increase in glucose uptake
(Fig. 3A) and 46% increase in glucose incorporation (Fig. 3B) com-
pared to controls. Consistent with this ﬁnding, analysis of glycogen
myocardial content revealed 123% increase of this metabolite in
basal OA group in relation to basal control group (Fig. 3C). The OA
hearts displayed a 45% decrease in glycogen content after ischemia
and reperfusion, indicating its utilization as an alternative energy
substrate during the ischemia (Fig. 3C). These results were corrobo-
rated by analysis of GLUT4 expression by Western blotting. GLUT4
is the predominant glucose transporter isoform in the adult heart.
Immunoblots of the 45 kDa GLUT4 and 62 kDa p-AMPK band and
semi-quantitative results of the analysis are shown in Fig. 4A and B.
In relation to p-AMPK, no differences were observed between the
groups (Fig. 4B).
We also found a stimulated glycolytic ﬂow in OA hearts, as shown
by increased G-6-P (260% increase in basal condition), F-6-P (21%Fig. 2. Cardiac tissue mRNA expression of PPARα (A), CPT-1 (B) and ACO (C) in C (control)
Data are means±SEM for n=5 animals; *pb0.05 vs C, and **pb0.01 vs C.increase in basal condition) (Fig. 5A and B, respectively) and lactate
(155%, 47% and 149% increase in pre-occlusion [20 min], occlusion
[15 min] and reperfusion [15 min], respectively) (Fig. 5C) levels, com-
pared with the control group. Reduction of the supply of nutrients,
induced by coronary occlusion, was reﬂected in a signiﬁcant decrease
in G-6-P (94% and 92% decrease in C and OA groups, respectively)
(Fig. 5A) and F-6-P (83% and 91% decrease in C and OA groups,
respectively) (Fig. 5B) contents. This fall can also be attributed to
the increased consumption imposed by intensiﬁed ﬂow of the glyco-
lytic pathway during the ischemic phase. As expected, the lactate
concentration in cardiac perfusate was increased immediately after
ischemia (267% and 112% increase in C and OA groups, respectively).
With the reperfusion, lactate production in the control hearts
returned to values similar to the baseline; however, the OA group
maintained the increase displayed during ischemia, conﬁrming
again their greater ability to use glucose (Fig. 5C).
The tissue energetic yield was improved with OA treatment,
showing a 261% increase in ATP production in the OA group, compared
to control, under basal conditions. After ischemia and reperfusion, theand OA (orotic acid) groups. Arbitrary units are relative to values obtained for β-actin.
Fig. 3. Glucose utilization by heart from control (C) and orotic acid (OA) treated rats. Uptake (A) and tissue incorporation (B) of [U-14C] glucose by hearts perfused with 3H-triolein,
[U-14C] glucose and insulin and glycogen concentration after basal perfusion (20 min) and post-occlusion and reperfusion (30 min) (C). Data are means±SEM for n=3–7 animals;
*pb0.05 vs C; ***pb0.001 vs C at basal condition, ##pb0.01 vs OA at basal condition.
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and 92% on ATP content in C and OA hearts, respectively (Fig. 6).
When we analyzed the contractility index, no changes were ob-
served in heart rate and diastolic tension under all perfusion condi-
tions. Nevertheless, dietary OA supplementation increased ventricular
systolic tension (22% and 25% increase in pre-ischemia and ischemia,
respectively),−dT/dt (37% and 46% increase in pre-ischemia and ische-
mia, respectively) and +dT/dt (18% increase in basal period) (Table 2).
During ischemia, coronary ﬂow decreased similarly in both groups
of hearts, but was higher in OA hearts during cardiac reperfusion, in
relation to control group (Table 2). After release of coronary artery
ligation, all of the hearts presented irreversible arrhythmias.
Discussion
As functional performance in the heart is closely related to its met-
abolic capacity, our study investigated the effect of a cardioprotective
agent, OA, on the pathways of energy supply, in conditions of normal
ﬂow and ischemia.
The diet supplemented with OA reduced the serum concentrations
of TG and cholesterol. In addition to the already established effects
of OA on the hepatic accumulation of fat, this study revealed an
increased activity of functional and total cardiac LPL, data that corrob-
orated our previous results from epididymal fat tissue (Ferreira et al.,
2008). The high lipoprotein lipase activity induced by OA intake,
apart from increasing the energy supply to cardiac tissue, may also
contribute to clearance of serum fat. The studies of Levak-Frank
(Levak-Frank et al., 1999) showed that expression of LPL only in the
heart is sufﬁcient to keep the plasma TG level within the normal
range.Fig. 4. Summary data of blots and representative Western blot of GLUT4 and p-AMPK.
Data are means±SEM for n=3 animals; *pb0.05.The analysis of the expressions of genes of the nuclear receptor
PPARα and its target genes, CPT-1 and ACO, revealed increase induced
by treatment with OA. The PPARα is highly expressed in the heart and
that the activity of this nuclear receptor is an important determinant
of lipid homeostasis and ATP production in cardiomyocytes, by regu-
lating the transcription of several proteins linked to the transport and
oxidation of FA. This would be another way to reduce the offer of FA
for hepatic production of TG and VLDL (Carroll and Severson, 2001;
Stavinoha et al., 2004).
The data of uptake and incorporation of triolein-FA by myocar-
dium conﬁrm the metabolic steps previously discussed. The dietary
supplementation with OA increased the uptake and the incorporation
of FA, both in the hearts perfused only with triolein, as those perfused
concurrently with triolein and glucose. Introduction of glucose in perfu-
sion buffer reduced the cardiac utilization of FA, conﬁrming previous
work (Dyck et al., 2004; Enriquez, 2002). Therefore, the changes in-
duced by OA in the activity of LPL and in the expressions of PPARα,
CPT-1 e ACO mRNA improved the cardiac uptake and oxidation of FA
and thus the tissue energy. This is particularly important in the ischemic
phase, when the recovery of cardiac function is entirely dependent
on the level of energy stores (Jennings and Steenbergen, 1985; Samaja
et al., 1998).
Regarding cardiac utilization of glucose, the results obtained
revealed increase of the mass of GLUT4 glucose transporter in OA
hearts, compared to controls. The perfusion of these hearts with a
mixture of glucose, insulin and triolein revealed major uptake of
glucose and consequent increase in incorporation of this metabolite.
Yet, the OA hearts showed major content of the glycolytic intermedi-
ates, G-6-P and F-6-P, during the basal perfusion and major produc-
tion of lactate in all conditions of analyzed perfusion, indicating a
stimulus of the glycolytic pathway. Our data suggest an isolated acti-
vation of the glycolytic pathway by OA, evidenced by increased
cardiac production of lactate even in baseline condition, in order to
feed ATP production for the maintenance of ionic homeostasis,
according to “energetic compartmentalization theory” (Dizon et al.,
1998; Weiss et al., 2006). For this concept, the modular organization
of the processes of energy production, consumption and distribution
obeys the spatial distribution of enzymatic systems within the car-
diomyocyte, so that the glycolytic enzymes, linked to sarcolemma,
are associated with channels and transporters of ions of the mem-
brane. Our data corroborate previous works, by showing that glyco-
lytic ﬂux was “more open”, permitting greater throughput of
intermediates with individually increased levels of selected metabo-
lites (Donohoe et al., 1993).
When we compared the concentration of glucose metabolites in
the different conditions of cardiac perfusion, we observed reduction
of G-6-P and F-6-P after ischemia and reperfusion, in the two groups.
It was noted also that the ischemia induced increase of lactate pro-
duction in both groups and the control group signiﬁcantly reduced
Fig. 5. Glycolytic intermediates of basal and ischemic hearts. Concentration of glucose-6-phosphate (A) and fructose-6-phosphate (B), present in myocardial tissue from C (control)
and OA (orotic acid) groups, after basal perfusion (20 min) and post-occlusion and reperfusion (30 min). Lactate concentration was determined in cardiac perfusate after basal
perfusion (20 min) and post-occlusion (15 min) and reperfusion (15 min). Data are means±SEM for n=7 animals; ###pb0.001 vs C at basal condition; +++pb0.001 vs OA at
basal condition; *pb0.05 vs C at basal condition; ○pb0.05 vs C at post-occlusion, ○○pb0.001 vs C at post-reperfusion, ●●pb0.01 vs C at post-occlusion, and ++pb0.01 vs OA at
basal condition.
Table 2
Functional parameters from hearts of C (control) and OA (orotic acid) animals.
C OA
Basal (n=18–22)
Heart rate (beats/min) 274±3.3 273±0.9
Systolic tension (g) 5.8±0.1 7.1±0.1**
Diastolic tension (g) 0.8±0.01 0.8±0.01
481L.C.J. Pôrto et al. / Life Sciences 90 (2012) 476–483this production with the reperfusion of hearts. These data evidence
the activation of glycolytic pathway during the ischemic phase, as
an alternative in order to produce energy for the myocardium, as pre-
viously reported by other authors (Depre et al., 1999; King and Opie,
1998; Sambandam and Lopaschuk, 2003).
The contribution of glycogen for the glycolytic pathway in ische-
mic condition is appreciable, and the results presented here revealed
a pre-ischemic increase of the myocardial content of glycogen in the
OA animals, corroborating previous works (Ferdinandy et al., 1998;
Munsch et al., 1989). The glycogen store in the OA hearts reduced
after ischemia, suggesting the use of this metabolite in energy
generation.
We could note that the metabolic changes caused by OA reﬂected,
as expected, in the increase of the myocardial content of ATP even
in pre-ischemia. This is interesting considering that the energeticFig. 6. Concentration of ATP present in cardiac tissue from C (control) and OA (orotic
acid) groups, after basal perfusion (20 min) and post-occlusion and reperfusion
(30 min). Data are means±SEM for n=7 animals; *pb0.001 vs C at basal condition,
###pb0.001 vs C at basal condition; +++pb0.001 vs OA at basal condition.reserve of the heart dictates the length of its resistance to the episode
of subsequent ischemia and reperfusion. The major availability of ATP
can minimize the post-ischemia and reperfusion intracellular ionic
overload and, thus, delays the cellular and functional impairment
(Jennings and Steenbergen, 1985; Samaja et al., 1998).
Despite the well-recognized importance of AMPK in the glucose
uptake and GLUT4 translocation (An et al., 2005; Sambandam and+dT/dt (g/s) 97±1.4 115±2.1**
−dT/dt (g/s) 92±2.3 125±4.4**
Coronary ﬂow (mL/min) 14.3±0.2 14.1±0.1
Occlusion (n=10–14)
Heart rate (beats/min) 257±1.2++ 254±1.4&&&
Systolic tension (g) 4.6±0.1+++ 5.8±0.1**,&&
Diastolic tension (g) 1.0±0.1 1.1±0.2
+dT/dt (g/s) 76±2.4+++ 84±3.5&&
−dT/dt (g/s) 57±1.1++++ 84±2.8****,&&&
Coronary ﬂow (mL/min) 6.5±0.5++++ 6.4±0.5&&&&
Reperfusion (n=10–14)
Diastolic tension (g) 3.2±0.2#### 3.2±0.2●●● ●
Coronary ﬂow (mL/min) 11.9±0.1#### 12.81±0.2*,○○○○
Data are means±SEM; *pb0.05, **pb0.01, ****pb0.0001 vs C; ++pb0.01, +++pb0.001,
++++pb0.0001 vs C at basal condition; ####pb0.0001 vs C at basal and occlusion
conditions; &&pb0.01, &&&pb0.001, &&&&pb0.0001 vs OA at basal condition;
●●● ●pb0.0001 vs OA at basal and occlusion conditions; ○○○○pb0.0001 vs OA at
occlusion condition.
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Fig. 7. Scheme of the metabolic changes evidenced by treatment with orotic acid. FFA: free fatty acids; LPL: lipoprotein lipase; PPARα: peroxisome proliferator-activated receptor α;
CPT-1: carnitine palmitoyltransferase-1; ACO: acyl-CoA oxidase; G-6-P: glucose-6-phosphate; F-6-P: fructose-6-phosphate, and ATP: adenosine triphosphate. : increased cardiac
uptake of glucose as evidenced by increased expression of the GLUT4 transporter; increased glycolytic ﬂux and glycogen synthesis and storage. : increased activity of cardiac LPL
and increased fatty acid uptake; increased fatty acid oxidation as evidenced by increased expression of the transcription factor PPARα and enzymes CPT-1 and ACO.
482 L.C.J. Pôrto et al. / Life Sciences 90 (2012) 476–483Lopaschuk, 2003), the current study demonstrated that the phos-
phorylation and activation of AMPK were similar in both groups.
The results obtained in this study, therefore, argue that other
factors besides AMPK activation are necessary to induce glucose
transport in normal hearts from orotic acid treated rats. Previous
studies have shown that the increase in contraction activates protein
kinase D (PKD) in cardiac myocytes independently of AMPK signaling,
and that the PKD activation is linked to contraction-induced GLUT4
translocation and GLUT4-mediated increase in glucose uptake
(Luiken et al., 2008). Other possibility is that increased supply of
intermediates for the synthesis of myocardial ATP by orotic acid
(Donohoe et al., 1993) provides enough cellular ATP levels to de-
crease the AMP:ATP ratio and consequent activation of AMPK.
The cardiac contractility indices are important indicators of func-
tional integrity in this organ. In this work, we could observe that the an-
imals given dietary OA presented major ventricular systolic strength
and −dT/dt, in the basal and ischemic conditions, besides major
+dT/dt at baseline, implicating better contractility and recovery of ven-
tricular relaxation. These data indicate that the OA treatment induced a
positive inotropic effect on these animals, what is due, at least in part, to
major energetic yield achieved. This allows us to suggest that the met-
abolic changes induced by OA were reﬂected in appreciable alterations
to the contractile function of myocardium in basal and ischemic condi-
tions. Unfortunately, it was not possible to evaluate contractile function
during reperfusion period, since all of the hearts, in both groups, pre-
sented irreversible arrhythmia. But it is noteworthy that the improved
recovery of the coronary ﬂow in OA animals during cardiac reperfusion,
would provide improved supply of energy substrates as well as cardiac
function.
Our data clarify for the ﬁrst time the mechanism of action of OA on
the energy supply of the heart. We can conclude that this compound
improves cardiac performance by acting on several metabolic steps,
increasing the cardiac utilization of glucose and FA and, thus, the
ATP pool (Fig. 7). The results of this study support the hypothesis
that the beneﬁcial contribution of OA is to the functional recovery
of the myocardium after the reperfusion stage.Conﬂict of interest statement
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